Showing results (81-90 of 112) with videos related to

Sort By:
Pageof 12
Tumori|June 8, 2022
Get up, stand up: Alongside adolescents and young adults with cancer for their right to be forgottenPaola Quarello, Angela Toss, Maurizio Mascarin, et al.
Diagnostics (Basel, Switzerland)|April 3, 2021
The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort StudyAngela Toss, Claudia Piombino, Elena Tenedini, et al.
Menopause (New York, N.Y.)|May 12, 2026
Association between risk-reducing salpingooophorectomy and bone health in women with hereditary breast and ovarian cancer syndromeSara De Vincentis, Giulia Brigante, Riccardo Cuoghi Costantini, et al.
Critical Reviews in Oncology/Hematology|June 4, 2026
Brain tumor susceptibility: from genetic predisposition syndromes to extended characterization of genomic determinantsMarta Aprile, Vanessa Callegari, Selene Cipri, et al.
Familial Cancer|May 14, 2026
Impaired glucose tolerance in women with BRCA1 versus BRCA2 pathogenic or likely pathogenic variants: Results from a prospective cohort studyGiovanni Grandi, Claudia Piombino, Giovanna Sighinolfi, et al.
Critical Reviews in Oncology/Hematology|May 8, 2024
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathwaysBrenno Pastò, Giulia Buzzatti, Clorinda Schettino, et al.
Journal of Oncology|July 14, 2020
Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in BRCA1/2: A Review of Secondary Prevention GuidelinesBoudewijn Dullens, Robin de Putter, Matteo Lambertini, et al.
NPJ Breast Cancer|December 13, 2025
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancerEmma Zattarin, Antonio Marra, Antonella Palazzo, et al.
Tumori|April 15, 2025
From walls to wonder: Talking about spaces tailored for adolescents and young adults with cancerCarlo Alfredo Clerici, Francesca Scotti, Elena Pagani Bagliacca, et al.
BMC Cancer|June 15, 2024
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER studyFabio Canino, Monica Barbolini, Ugo De Giorgi, et al.
Pageof 12